Piperacillin/tazobactam for Bacterial Infection

Phase-Based Progress Estimates
Surrey Memorial Hospital - Fraser Health Authority, Surrey, CanadaBacterial Infection+2 MorePiperacillin/tazobactam - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether piperacillin-tazobactam is as good as meropenem for treating blood-stream infections caused by bacteria that are resistant to cephalosporins.

Eligible Conditions
  • Beta-Lactam Antibiotic Resistance Bacterial Infection
  • Bacterial Blood Infection
  • Enterobacteriaceae Infections

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

0 Primary · 12 Secondary · Reporting Duration: 30 days and 90 days from randomization

Day 90
All-cause mortality
Day 30
Treatment failure
Day 90
Recurrent positive blood cultures (relapse)
Total antibiotic days
Total in-hospital days
30 days from randomization
Adverse events
Day 14
Microbiological failure
90 days from randomization
Carriage of carbapenemase-producing Enterobacteriaceae (CPE) and non-CPE carbapenem-resistant Enterobacteriaceae in-hospital
Clinically or microbiologically documented infection other than Gram-negative bacteremia
Clostridium difficile associated diarrhea
Development of resistance
Number of hospital re-admissions

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

1 of 2
piperacillin tazobactam
1 of 2

Active Control

Experimental Treatment

1084 Total Participants · 2 Treatment Groups

Primary Treatment: Piperacillin/tazobactam · No Placebo Group · Phase 4

piperacillin tazobactam
Experimental Group · 1 Intervention: Piperacillin/tazobactam · Intervention Types: Drug
ActiveComparator Group · 1 Intervention: Meropenem · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days and 90 days from randomization

Who is running the clinical trial?

Tel Aviv Medical CenterOTHER
23 Previous Clinical Trials
7,784 Total Patients Enrolled
Hadassah Medical OrganizationOTHER
702 Previous Clinical Trials
179,982 Total Patients Enrolled
McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER
406 Previous Clinical Trials
126,102 Total Patients Enrolled
University of Modena and Reggio EmiliaOTHER
84 Previous Clinical Trials
29,270 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,248 Previous Clinical Trials
24,677,579 Total Patients Enrolled
Soroka University Medical CenterOTHER
184 Previous Clinical Trials
56,024 Total Patients Enrolled
Rabin Medical CenterOTHER
401 Previous Clinical Trials
123,449 Total Patients Enrolled
Jewish General HospitalOTHER
136 Previous Clinical Trials
318,599 Total Patients Enrolled
Meir Medical CenterOTHER
381 Previous Clinical Trials
79,865 Total Patients Enrolled
The Chaim Sheba Medical CenterOTHER
15 Previous Clinical Trials
5,439 Total Patients Enrolled
Rambam Health Care CampusLead Sponsor
493 Previous Clinical Trials
337,963 Total Patients Enrolled
Leonard Leibovici, MDStudy DirectorRabin Medical Center
Cristina Mussini, MDStudy DirectorUniversity of Modena and Reggio Emilia
Noa Eliakim-Raz, MDStudy DirectorRabin Medical Center, Beilinson Campus
1 Previous Clinical Trials
1,000 Total Patients Enrolled
Roni Bitterman, MDPrincipal InvestigatorRambam Health Care Campus
1 Previous Clinical Trials
1,000 Total Patients Enrolled
Mical Paul, MDStudy DirectorRambam Health Care Campus
9 Previous Clinical Trials
4,966 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Bacterial infections acquired in the community or hospital are both allowed.

Frequently Asked Questions

What is the sample size of this medical experiment?

"Affirmative. As per the information hosted on clinicaltrials.gov, this research is actively recruiting participants; it was launched May 1st 2019 and has been amended for the last time as of July 25th 2022. The study necessitates 1084 patients across a single site." - Anonymous Online Contributor

Unverified Answer

To what extent can Piperacillin/tazobactam be relied upon for patient safety?

"Having already been approved, the safety of Piperacillin/tazobactam is rated highly and given a score of 3." - Anonymous Online Contributor

Unverified Answer

Is registration for this clinical trial currently available to patients?

"The information found on clinicaltrials.gov demonstrates that this trial is actively enrolling patients as of now. This programme was initially posted in May 2019 and revised most recently in July 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.